-
In category NewsGSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
On March 14th, 2023, GSK announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. Invasive meningococcal disease (IMD), a major cause of meningitis and septicaemia, is an uncommon […]